Cancer — Expanded Access Programs
Overview
Right2Hope maintains a directory of 55 expanded access programs, clinical trials, and compassionate use pathways listed for Cancer. Each entry below was sourced from sponsor disclosures and public clinical-trial registries. Use this hub to understand the breadth of ongoing research, identify sponsors with cancer programs, and link out to specific protocols for eligibility, contact, and request details. Of these, 17 programs are currently active or recruiting, with the remaining 38 in other lifecycle stages. Sponsors actively running programs in this area include A2 Biotherapeutics Inc., Bayer, Bristol-Myers Squibb, Children's Hospital of Philadelphia, Monopar Therapeutics, and others.
By recruiting status
Snapshot of where every Cancer program currently sits in its lifecycle.
- Active / Recruiting17
- Inactive38
Top sponsors
Organisations running the most Cancer programs in the directory.
- A2 Biotherapeutics Inc.3 programs
- Bayer2 programs
- Bristol-Myers Squibb2 programs
- Children's Hospital of Philadelphia2 programs
- Monopar Therapeutics2 programs
- OncoResponse, Inc.2 programs
- Aadi Bioscience, Inc.1 program
- AbbVie1 program
- Actuate Therapeutics Inc.1 program
- Agenus Inc.1 program
Cancer programs (55)
Sorted by recruiting status, then alphabetically by program name. Click any program to view eligibility, locations, and sponsor contact details.
- Study on 9-ING-41 for Patients with Advanced Cancers — Actuate Therapeutics Inc.
- Study on KB707 for Treating Advanced or Metastatic Solid Tumors — Krystal Biotech, Inc.
- Study on the Safety and Effectiveness of A2B395 CAR T-Cell Therapy for Solid Tumors with Specific Genetic Markers — A2 Biotherapeutics Inc.
- Study on the Safety and Effectiveness of A2B530 CAR T-Cell Therapy for Solid Tumors with CEA Expression and HLA-A*02 Loss — A2 Biotherapeutics Inc.
- Study on ACTengine® IMA203/IMA203CD8 Alone or with Nivolumab for Treating Recurrent or Hard-to-Treat Solid Tumors — Immatics US, Inc.
- Extension Study for Patients Continuing Venetoclax Treatment from Previous Trials — AbbVie
- Study on ENB003 and Pembrolizumab for Treating Solid Tumors — ENB Therapeutics, Inc
- Expanded Access to Neoantigen Synthetic Long Peptide Vaccines for Patients with Local or Metastatic Solid Tumors — Jaime Leandro Foundation for Therapeutic Cancer Vaccines
- Access to BAY2927088 for Treating Advanced Non-Small Cell Lung Cancer with HER2 Mutation — Bayer
- Study on FOG-001 for Advanced or Metastatic Solid Tumors — Fog Pharmaceuticals, Inc.
- Expanded Access Program for MNPR-101-DFO*-89Zr in Patients with Solid Tumor Cancer — Monopar Therapeutics
- Expanded Access Program for MNPR-101-PCTA-177Lu in Patients with Solid Tumor Cancer — Monopar Therapeutics
- Study on the Safety and Effectiveness of ST-067 in Patients with Advanced Solid Tumors — Simcha IL-18, Inc.
- Continuation Study for Patients Who Completed a Previous Cancer Study with Durvalumab — AstraZeneca
- Study on the Safety and Effects of MBRC-101 in Treating Advanced Solid Tumors — MBrace Therapeutics
- Study on Selpercatinib Before Radioactive Iodine in Patients with RET Fusion Thyroid Cancer (RAISE) — Children's Hospital of Philadelphia
- Split-Dose R-CHOP Chemotherapy for Older Adults with Diffuse Large B-Cell Lymphoma (DLBCL) — University of Wisconsin, Madison
- Study on KVA12123 Treatment Alone and with Pembrolizumab for Advanced Solid Tumors (VISTA-101) — Kineta Inc.
- Study on Sarilumab and Capecitabine for Treating Advanced and High-Risk Breast Cancer — University of Southern California
- Phase 2 Study on the Effectiveness and Safety of Atezolizumab and Tiragolumab for Cancer of Unknown Primary — M.D. Anderson Cancer Center
- Phase 2 Study of Firi-cel for Patients with Relapsed or Hard-to-Treat Large B-cell Lymphoma — CARGO Therapeutics
- Study on Zotiraciclib for Recurrent Brain Tumors with IDH1 or IDH2 Mutations — National Cancer Institute (NCI)
- A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study — Hoffmann-La Roche
- Study on BIO-106 Alone and with Pembrolizumab for Advanced Cancers — BiOneCure Therapeutics Inc.
- Study on AdAPT-001 for Patients with Sarcoma and Hard-to-Treat Solid Tumors — EpicentRx, Inc.
- Study on BMS-986253 with Nivolumab or Nivolumab Plus Ipilimumab for Advanced Cancers — Bristol-Myers Squibb
- Study on OR2805, a Monoclonal Antibody Targeting CD163, Alone and with Other Cancer Treatments — OncoResponse, Inc.
- Study on OR502, a Monoclonal Antibody Targeting LILRB2, Alone and with Other Cancer Treatments — OncoResponse, Inc.
- Study on the Safety and Effectiveness of A2B694 CAR T-Cell Therapy for Solid Tumors with MSLN Expression and HLA-A*02 Loss — A2 Biotherapeutics Inc.
- Study on TLPO Cancer Vaccine for Solid Tumors — Elios Therapeutics, LLC
- Comparing Chemotherapy and Immunotherapy with Radiation for Head and Neck Cancer — Loren Mell, MD
- Study on Durvalumab and Tremelimumab for Treating Advanced Rare Solid Tumors — Prisma Health-Upstate
- Study on Azeliragon and Stereotactic Radiation Therapy for Patients with Brain Metastases — Baptist Health South Florida
- Study on Genomic Testing and Targeted Therapies for Cancer — Rachel Miller
- Expanded Access Program for Cancer Treatment with Balstilimab and Zalifrelimab — Agenus Inc.
- Access to AVM0703 for Patients with Solid Tumors and Blood Cancers — AVM Biotechnology Inc
- Investigation of Profile-related Evidence Determining Individualized Cancer Therapy for Patients With Aggressive Malignancies and Poor Prognoses — Medical College of Wisconsin
- Study on Isa-Rd Treatment for Older or Frail Patients with Newly Diagnosed Multiple Myeloma — UNC Lineberger Comprehensive Cancer Center
- Study on Using Larotrectinib to Improve Radioactive Iodine Treatment in Differentiated Thyroid Cancer — Children's Hospital of Philadelphia
- Study on Lattice Radiotherapy for Improved Treatment of Large Tumors — University of Cincinnati
- Study for Ongoing Safety Monitoring of a Study Drug — Eli Lilly and Company
- Study on Oral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed Glioblastoma Multiforme (GBM) — Northwell Health
- Pan Tumor Rollover Study on Long-Term Safety of Nivolumab and Other Cancer Treatments — Bristol-Myers Squibb
- Study on Personalized Multi-peptide Vaccination with XS15 for Cancer Patients — University Hospital Tuebingen
- Study on SQ3370 for Patients with Advanced Solid Tumors — Shasqi, Inc.
- Preoperative Immunotherapy for Patients with Head and Neck Squamous Cell Carcinoma — Alain Algazi
- Study on Sirolimus with Metronomic Chemotherapy for Children with Recurrent or Hard-to-Treat Solid and Brain Tumors — Emory University
- Study of INKmune in Patients With mCRPC (CaRe Prostate) — Inmune Bio, Inc.
- Study on RP1 Alone and Combined with Nivolumab for Advanced Solid Tumors — Replimune Inc.
- Study on SAR444881 Alone and with Other Treatments for Advanced Solid Tumors — Sanofi
- Study on the CDK4/6 Inhibitor Abemaciclib for Solid Tumors with Genetic Changes in D-type Cyclins or CDK4/CDK6 Amplification — Dana-Farber Cancer Institute
- Study to Continue Darolutamide Treatment for Patients from Previous Bayer Studies — Bayer
- Study on Tadalafil and Pembrolizumab for Recurrent or Metastatic Head and Neck Cancer — University of California, San Diego
- Study on Nab-Sirolimus and Letrozole for Advanced or Returning Endometrioid Endometrial Cancer — Aadi Bioscience, Inc.
- UCSD Study on Image-Guided Radiosurgery to Protect Brain Function in Patients with Brain Metastases — Jona Hattangadi-Gluth
About this hub
Expanded access programs (sometimes called compassionate use, named-patient programs, or pre-approval access) allow patients with serious or life-threatening conditions such as Cancer to receive an investigational therapy outside of a controlled clinical trial when no comparable approved option is available. Eligibility, location, and the application process differ for each program — review the individual program pages below for sponsor contact information, inclusion criteria, and the request workflow. Right2Hope is a 501(c)(3) nonprofit and provides this directory free of charge for patients, caregivers, and treating physicians.
Looking for a different condition? Browse the full Cancer Type hub directory or search the full expanded access program catalog.